



Universiteit  
Leiden  
The Netherlands

## Cardiovascular risk assessment in diabetes

Djaberi, R.

### Citation

Djaberi, R. (2014, September 4). *Cardiovascular risk assessment in diabetes*. Retrieved from <https://hdl.handle.net/1887/28524>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/28524>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/28524> holds various files of this Leiden University dissertation

**Author:** Djaberi, Roxana

**Title:** Cardiovascular risk assessment in diabetes

**Issue Date:** 2014-09-04

## CHAPTER 9

---

### **Relationship between Vascular Stiffness and Stress Myocardial Perfusion Imaging in Asymptomatic Patients with Diabetes**

Roxana Djaberi, Cornelis J. Roos, Joanne D. Schuijf, Eelco J. de Koning, Ton J. Rabelink, Jan W. Smit, Alberto M. Pereira, Imad Al Younis, Bernies van der Hiel, Arthur J. Scholte, Jeroen J. Bax, J. Wouter Jukema.

*Eur J Nucl Med Mol Imaging.* 2011; 38:2050-2057

## ABSTRACT

### Purpose

Vascular stiffness may potentially be used as a screening tool to identify asymptomatic patients with diabetes with abnormal myocardial perfusion. The purpose of this study was therefore to determine the association between vascular stiffness measured with pulse wave velocity (PWV) and augmentation index (AIx), and abnormal myocardial perfusion imaging (MPI) in asymptomatic patients with diabetes.

### Methods

Prospectively, 160 asymptomatic patients with diabetes (mean age 51 yrs, male 87) underwent MPI with adenosine stress. Summed stress score (SSS) was determined per patient according to a 17 segment and 5 point score. Abnormal MPI (SSS  $\geq 3$ ) was sub-classified as moderate (SSS 3-7) or severe (SSS  $\geq 8$ ) MPI defects. Using applanation tonometry, the carotid-femoral PWV and the radial AIx corrected to 75 beats per minute were determined non-invasively.

### Results

MPI was abnormal in 61 patients (38%), with severe MPI defects in 22 patients (14%). Mean PWV increased with deteriorating MPI from  $8.4 \pm 2.2$  m/s in normal MPI to  $9.0 \pm 2.2$  m/s in moderate MPI defects ( $P = 0.11$ ), and to  $11.1 \pm 2.5$  m/s in severe MPI defects ( $P < 0.01$ ). Likewise, mean AIx increased from  $18.4 \pm 13.4\%$  to  $19.4 \pm 10.7\%$  ( $P = 0.66$ ) and to  $25.4 \pm 9.0\%$  ( $P = 0.03$ ). After adjustment for age and other risk factors, PWV remained a significant predictor of severe MPI defects ( $P = 0.01$ , OR 1.50, 95% CI 1.11-2.00), whereas AIx was no longer significant ( $P = 0.20$ ).

### Conclusions

Vascular stiffness measured by PWV is associated with severe MPI defects in asymptomatic patients with diabetes.

## INTRODUCTION

It is considered that the global prevalence of diabetes will approximately double in the next two decades [1]. Diabetes is associated with a marked increase in the incidence of cardiovascular morbidity and mortality, mainly attributable to coronary artery disease (CAD). Moreover, the presence and progression of CAD in diabetic patients is often asymptomatic, leading to more extensive disease at the time of diagnosis [2]. Since a delayed diagnosis of CAD considerably worsens the prognosis, early recognition of CAD could lead to more effectively targeted intervention and reduce morbidity and mortality in this population. Myocardial perfusion imaging (MPI) with SPECT is most commonly applied to identify patients with CAD and can accurately identify patients at increased cardiovascular risk [2-4]. However, based on recent data, a wide ranged routine MPI screening strategy of all asymptomatic patients with diabetes appears to be ineffective [5]. Accordingly, a selective "prescreening" strategy using an initial test for the identification of patients with a higher likelihood of abnormal MPI followed by referral of only these patients to MPI may be preferred. Non-invasive assessment of vascular stiffness could represent a promising tool for this purpose. In several studies, a relation between vascular stiffness and cardiovascular disease has been observed [6-8]. Assessment of the vascular stiffness, by means of pulse wave velocity (PWV) or pulse wave analysis (PWA) for augmentation index (AIx), may therefore have the potential to serve as a marker of abnormal MPI. Although PWV and AIx have been extensively studied in the general population [9-13], less data are available concerning their relation with CAD in asymptomatic patients with diabetes.

The aim of the current study was to prospectively assess the relation between the non-invasive measures of vascular stiffness (PWV and AIx) with the presence and extent of myocardial perfusion defects as assessed by SPECT MPI, in asymptomatic patients with diabetes.

## METHODS

### Study population

Prospectively, 160 consecutive asymptomatic patients with diabetes were recruited from a routine outpatient clinic. Patients were referred to the cardiology outpatient clinic for risk assessment and cardiovascular screening. Anginal symptoms were ruled out using a self-completed questionnaire for encountered chest pain [14]. The American Diabetes association (ADA) criteria were used to identify diabetes and for further stratification in type 1 or 2 diabetes [15]. Patients were considered as having type 1 diabetes if laboratory analysis demonstrated auto-antibodies to islet cells, insulin and glutamic acid decarboxylase or low levels of plasma c-peptide. Otherwise, patients were

considered to have type 2 diabetes. Medical history and demographics were obtained. All patients underwent physical examination, and blood and urine laboratory testing. MPI was performed as part of clinical work-up to determine presence and extent of myocardial perfusion defects. Additional measurements of PWV and AIx were used to assess vascular stiffness.

### **Cardiovascular risk factors**

Cardiovascular risk factors were defined according to the following criteria: positive family history for CAD (presence of CAD in first degree family members male <55 years and / or female <65 years), smoking (current smoking or smoking in the last 2 years), hypertension (blood pressure >140/90 mmHg or treatment with antihypertensive medication), body mass index (kg/m<sup>2</sup>), hypercholesterolemia (total cholesterol level >5.0 mmol/L or use of cholesterol lowering medication), and micro-albuminuria (urine albumin/creatinine ratio  $\geq$ 3.5 mg/mmol) [2]. Plasma hemoglobin A1c was determined as a measure of glycemic control.

### **SPECT myocardial perfusion imaging**

#### *SPECT data acquisition*

ECG-gated adenosine technetium-99m sestamibi (Tc99m MIBI) SPECT MPI was performed using a 2-day protocol, comprising of stress imaging on the first day and a rest scan on the second day [16]. Anti-hypertensive treatment with beta-adrenergic blocking agents or calcium antagonists was stopped and patients were instructed to abstain from caffeine containing products 24 hours prior to the stress test. Vasodilator stress was induced by intravenous infusion of adenosine 140  $\mu$ g/kg/min for 6 min, with simultaneous handgrip exercise. Tc99m MIBI (500MBq) was injected intravenously after the third minute. Blood pressure and a 12-lead ECG were recorded throughout the adenosine infusion.

Images were acquired 2 hours after radiopharmaceutical injection using a triple head SPECT gamma camera (GCA 9300/HG; Toshiba Corporation, Tokyo, Japan) with low-energy, high-resolution collimators. Image acquisition was performed, using a circular 360° orbit, 60 projections, and 40 seconds per projection, in compliance with the American Society of Nuclear Cardiology (ASNC) imaging guidelines. Images were processed to obtain the short-axis, vertical long-axis, and horizontal long-axis sections, as well as polar map formats, normalized to maximal myocardial activity [16]. Patient motion was reviewed by examining the raw cine images. No attenuation or scatter correction was used.

### *SPECT data analysis*

For semi-quantitative visual interpretation the myocardium was divided into 17 segments according to ASNC guidelines [16]. Tracer uptake in each segment was evaluated in consensus by two expert observers, blinded to patient's clinical characteristics and test results, using a 5-point scoring system ranging from 0 (normal uptake) to 4 (absent uptake). The summed stress score (SSS) was determined by the total sum of the 17 segmental scores of the stress images. MPI was considered normal if  $SSS < 3$ . In case of abnormal MPI, a  $SSS 3-7$  was considered to represent moderate MPI defects, and a  $SSS \geq 8$  to represent severe MPI defects [17]. Finally, regional wall motion on gated SPECT images was evaluated to allow differentiation between true MPI abnormalities and diaphragmatic or breast attenuation artifacts.

### **Assessment of Vascular Stiffness**

Measurements were derived and analyzed non-invasively by applanation tonometry using a Sphygmocor system (SphygmoCor, Atcor Medical, Sydney, Australia). All measurements were performed in the morning in a quiet, temperature controlled clinical research laboratory by a specially trained technologist, blinded to patient's clinical characteristics and test results. Patients were instructed to abstain from their morning medication and remain fasting until after the test. Assessment of PWV and PWA commenced following a 10 minute rest in supine position, after a state of constant heart rate and blood pressure was reached.

### *Pulse wave velocity*

The pulse waves were recorded at the common carotid artery and the femoral artery by sequential tonometry with simultaneous electrocardiographic gating. Pulse transit time was determined as the average of 10 consecutive beats. The distance between the two sites was measured. Aortic PWV (m/s) was defined as the distance between the 2 recording sites traveled by the pulse wave, divided by transit time. Using system software, aortic PWV was determined semi-automatically. The validation and reproducibility of this semi-automatic method have been previously published [18]. Measurements were performed three times in each patient and averaged to obtain the mean aortic PWV.

### *Pulse wave analysis*

The peripheral pressure waveforms were recorded from the radial artery at the wrist, with a hand-held high fidelity tonometer (Millar Instruments, Houston, TX, USA) and calibrated by peripheral blood pressures of the brachial artery [7,19]. The corresponding central aortic pressure waveform was generated by a validated generalized transfer function. The central aortic pressure waveform was analyzed to identify the first shoulder

of the pressure wave representing the incident wave attributable to left ventricular ejection. The merging point of the incident and the reflected wave (the inflection point) was then identified on the generated aortic pressure waveform. The absolute augmented pressure was the maximum systolic pressure minus pressure at the inflection point. Subsequently, the AIx was defined as the absolute augmented pressure divided by the pulse pressure and expressed as a percentage [7,8].

Finally, the AIx was normalized for the heart rate of 75 bpm (AIx@75). For each patient, 3 consecutive waveform recordings were averaged to obtain the mean AIx@75, which was used for statistical analysis.

### **Statistical analysis**

Continuous variables were expressed as means  $\pm$  standard deviation and categorical variables as numbers (percentages). Firstly, associations of PWV and AIx@75 with baseline clinical risk factors were assessed using the Pearson's correlation coefficient ( $r$ ) or the Spearman's rank correlation coefficient ( $r_s$ ) in case of dichotomous variables. Secondly, differences in the mean PWV and AIx@75 for each group of MPI results were evaluated with the independent T-test. Thereafter, with univariate logistic regression analysis potential predictors of severe MPI defects were identified. Subsequently, all potential predictors were analyzed in a multivariate logistic regression model to identify the independent predictors of severe MPI defects. Additionally, patients were categorized according to PWV quartiles and for each quartile the prevalence of severe MPI defects was obtained. Subsequently, global chi square analysis was used to determine the incremental predictive value of PWV over baseline characteristics. Thereafter, using receiver operating characteristic (ROC) curve analysis two cut-off values were chosen for PWV; one cut-off value for the detection of severe MPI defects with optimal sensitivity and specificity and another cut-off value for the exclusion of severe MPI defects with optimal sensitivity and negative predictive value. All statistical analyses were performed using SPSS software (version 16.0, Inc., Chicago, Illinois). P-values  $<0.05$  were considered statistically significant.

## **RESULTS**

### **Patient characteristics**

The study population comprised of 160 asymptomatic diabetic patients. Baseline characteristics are provided in Table 1.



**Table 1** Baseline characteristics of the study population, n =160

Clinical factors	Mean $\pm$ st dev. or number (%)
Age	51 $\pm$ 12
Men	87 (54%)
Type 2 diabetes	91 (57%)
Diabetes duration (years)	15 $\pm$ 13
Insulin use	125 (78%)
Family history of CAD <sup>a</sup>	75 (47%)
Smoking	42 (26%)
Body mass index (kg/m <sup>2</sup> )	28 $\pm$ 6
HbA1c (mmol/l) <sup>b</sup>	8.2 $\pm$ 1.7
Hypertension	92 (58%)
Use of antihypertensive medication	76 (48%)
ACE-inhibitor use <sup>c</sup>	43 (27%)
Beta-blocker use	19 (12%)
Systolic blood pressure (mmHg)	133 $\pm$ 16
Diastolic blood pressure (mmHg)	80 $\pm$ 9
Hypercholesterolemia	107 (67%)
Cholesterol lowering medication	73 (46%)
Total cholesterol (mmol/l)	4.8 $\pm$ 1.1
Micro-albuminuria	39 (24%)
Aspirin use	31 (19%)

<sup>a</sup>CAD = coronary artery disease

<sup>b</sup>HbA1c = plasma hemoglobin A1c

<sup>c</sup>ACE = angiotensin converting enzyme


### SPECT myocardial perfusion imaging

The overall mean SSS was 3.1  $\pm$  4.1 (range 0-21). Abnormal MPI (SSS  $\geq$ 3) was observed in 60 patients (38%), including moderate MPI defects (SSS 3-7) in 38 patients (24%) and severe MPI defects (SSS  $\geq$ 8) in 22 patients (14%).

### Vascular Stiffness

#### *Pulse wave velocity*

The overall mean PWV was 8.9  $\pm$  2.4 m/s. PWV was associated with age ( $r = 0.62$ ,  $P < 0.01$ ), type 2 diabetes ( $r_s = 0.23$ ,  $P < 0.01$ ), diabetes duration ( $r = 0.30$ ,  $P < 0.01$ ), body mass index ( $r = 0.22$ ,  $P < 0.01$ ), hypertension ( $r_s = 0.43$ ,  $P < 0.01$ ), and micro-albuminuria ( $r = 0.29$ ,  $P < 0.01$ ).



**Figure 1** Relation between parameters of vascular stiffness and the extent of MPI defects as assessed by SPECT MPI. **a** Mean aortic PWV was increased in patients with abnormal MPI. The most substantial increase in PWV was observed in patients with severe MPI defects. **b** The relationship between mean AIx@75 and MPI shows a similar trend. Abbreviations: MPI = myocardial perfusion imaging and @ 75 = corrected for heart rate to 75 bpm.

As shown in Figure 1a, mean PWV increased only slightly from  $8.4 \pm 2.2$  m/s in patients with normal MPI to  $9.0 \pm 2.2$  m/s in patients with moderate MPI defects ( $P = 0.11$ ). However, the mean PWV was significantly higher in patients with severe MPI defects ( $11.1 \pm 2.5$  m/s,  $P < 0.01$ ).

#### *Association between pulse wave analysis with myocardial perfusion*

The mean AIx was  $21.1 \pm 12.3\%$  in the total population. Normalization for a heart rate of 75 beats per minute resulted in an overall mean AIx@75 of  $19.6 \pm 12.4\%$ . A significant association was observed between AIx@75 and the following risk factors: age ( $r = 0.47$ ,  $P < 0.01$ ), male gender ( $r_s = -0.43$ ,  $P < 0.01$ ), type 2 diabetes ( $r_s = 0.30$ ,  $P < 0.01$ ), hypercholesterolemia ( $r_s = 0.17$ ,  $P < 0.03$ ), and micro-albuminuria ( $r = 0.26$ ,  $P < 0.01$ ).

After stratification of mean AIx@75 according to SPECT MPI results, a trend similar to that of PWV was observed. Likewise, mean AIx@75 was slightly higher in patients with moderate MPI defects than in those with normal MPI ( $19.4 \pm 10.7\%$  and  $18.4 \pm 13.4\%$  respectively,  $P = 0.66$ ), and was significantly higher in patients with severe MPI ( $25.4 \pm 9.0\%$ ,  $P = 0.03$ ; Figure 1b).

**Table 2** Predictors of severe MPI defects (SSS  $\geq 8$ ) on SPECT

Clinical characteristic	Exp $\beta$ (95% CI)	P-value	Exp $\beta$ (95% CI)	P-value
Age	1.09 (1.04-1.14)	<0.01	1.06 (0.98-1.14)	0.16
Male gender	3.30 (1.15-9.45)	0.03	6.35 (1.47-27.41)	0.01
Type 2 diabetes	1.47 (0.55-3.90)	0.44		
Diabetes duration (years)	1.02 (0.99-1.06)	0.15		
Family history of CAD <sup>a</sup>	1.16 (0.47-2.85)	0.75		
Smoking	3.80 (1.48-9.77)	0.01	5.74 (1.35-24.46)	0.02
Body mass index (kg/m <sup>2</sup> )	0.99 (0.91-1.07)	0.77		
HbA1c (mmol/l) <sup>b</sup>	1.28 (1.00-1.65)	0.05	1.52 (1.03-2.25)	0.03
Hypertension	1.98 (0.73-5.41)	0.18		
Hypercholesterolemia	1.65 (0.57-4.79)	0.36		
Micro-albuminuria	3.86 (1.52-9.81)	0.01	1.05 (0.26-4.27)	0.95
PWV <sup>c</sup>	1.49 (1.22-1.81)	<0.01	1.49 (1.11-2.00)	0.01
AIx@75 <sup>d</sup>	1.06 (1.01-1.11)	0.02	1.05 (0.97-1.14)	0.20


MPI = myocardial perfusion imaging

<sup>a</sup>CAD = coronary artery disease


<sup>b</sup>HbA1c = plasma hemoglobin A1c

<sup>c</sup>PWV = Pulse wave velocity (in m/s)

<sup>d</sup>AIx@75 = Augmentation index (%) normalized for the heart rate of 75 bpm.



**Figure 2** Prevalence of patients with severe MPI defects per PWV quartile. The prevalence of severe MPI defects increased with increasing PWV. Of note, the prevalence of severe MPI defects chiefly increased in the third and fourth PWV quartile. Abbreviations: MPI = myocardial perfusion imaging.



**Figure 3** Incremental predictive value of PWV for the detection severe MPI defects as shown by an increase in global chi square. Addition of PWV to a model with baseline clinical risk factors age, gender, and smoking provided a significant incremental predictive value.

### Predictors of severe myocardial perfusion defects


As illustrated in Table 2, age, gender, smoking, HbA1c, micro-albuminuria, and both PWV and AIx@75 were identified as potential predictors of severe MPI defects in a univariate logistic regression model. Of note, after adjustment for age, gender, smoking, HbA1c, and micro-albuminuria, the PWV remained a significant predictor of severe MPI defects ( $P = 0.01$ ), whereas the AIx@75 was no longer significant.

As demonstrated in Figure 2, the prevalence of severe MPI defects gradually increased per PWV quartile. Importantly, in none of the patients in the lowest PWV quartile severe MPI defects were present. Also, only a relatively small proportion of patients (5%) in the second PWV quartile had severe MPI defects. In contrast, the prevalence of severe MPI defects increased to 20% in the third PWV quartile, while reaching 30% in the fourth quartile. Moreover, the addition of PWV to a model with baseline clinical risk factors age, gender, and smoking for the prediction of severe MPI defects showed significant incremental value of PWV (Figure 3).

ROC curve analysis for the detection of severe MPI defects showed highest sensitivity and specificity (77% and 75% respectively) with a PWV cut-off value of 9.8 m/s. An optimal sensitivity of 91% with an associated negative predictive value of 98% for the exclusion of severe MPI defects was found using a cut-off value of 9.2 m/s for PWV (Figure 4).

## DISCUSSION

In the present study of asymptomatic patients with diabetes, vascular stiffness as assessed by PWV and AIx was increased in the presence of severe MPI defects. PWV was



**Figure 4** Detection of severe MPI defects on SPECT by PWV. **a** ROC curve analysis for the detection of severe MPI defects yielded an optimal sensitivity and specificity of 77% and 75% with a PWV cut-off value of 9.8 m/s. **b** In contrast, optimization for the exclusion of severe MPI defects resulted in a cut-off value of 9.2 m/s with a sensitivity of 91% and corresponding negative predictive value of 98%. ROC = receiver operating characteristics.

independently associated with severe MPI defects, whereas AIx lost significance after correction for other cardiovascular risk factors and PWV. Addition of PWV to a model of baseline clinical risk factors showed significant incremental value for the prediction of severe MPI defects. Furthermore, ROC curve analysis revealed a moderate to good sensitivity of 77% and a specificity of 75% for the detection of severe MPI defects, with a PWV cut-off value of 9.8 m/s. Conversely, changing the cut-off value to 9.2 m/s resulted in a high sensitivity of 91% and negative predictive value of 98% for the exclusion of severe MPI defects. Accordingly, the current results indicate that non-invasive evaluation of vascular stiffness may be a practical tool to prescreen asymptomatic patients with diabetes for the differentiation in a higher and lower likelihood of abnormal MPI.

### Vascular stiffness and relationship to CAD

In the general population the relation between vascular stiffness and the presence of CAD has been confirmed in a considerable number of studies. Vascular stiffness measured as PWV or AIx is not only directly associated with the presence and severity of CAD on invasive coronary imaging [10], but also has incremental prognostic value for predicting cardiovascular events [9,11-13]. A recent meta-analysis (15877 subjects, 17 studies, average

follow-up of 7.7 years) showed that the risk of cardiovascular events increased a two-fold in patients with increased PWV [22]. Moreover, the predictive ability of PWV was shown to be even higher in patients with elevated baseline cardiovascular risk, supporting a role for PWV in high-risk populations such as patients with diabetes.

A few studies have specifically evaluated vascular stiffness in patients with diabetes. Cruickshank et al. evaluated the prognostic value of PWV for all-cause and cardiovascular mortality in 397 patients with diabetes with or without CAD. During a mean follow-up of 10.7 years, aortic PWV was an independent predictor for all-cause and cardiovascular mortality [23]. Additionally, Hatsuda et al. found in 595 patients with diabetes that PWV was significantly increased in 70 patients with established CAD [24]. Finally, Fukui et al. investigated 208 consecutive patients with type 2 diabetes and reported that AIx was significantly higher in 47 patients with previously confirmed CAD [21]. These observations indicate that markers of vascular stiffness may indeed be associated with CAD in patients with diabetes.

However, to our knowledge this is the first study in which PWV and AIx were applied in asymptomatic patients with diabetes to prospectively identify the presence of CAD defined by the presence of (severe) MPI defects. Although both PWV and AIx were increased in patients with severe MPI defects, only PWV was shown to be an independent predictor of severe MPI defects. These observations are in agreement with the previous literature as also in the general population more discrepant results have been reported using AIx as compared to PWV [25,26].

Possibly, the more variable results with AIx may be explained by underlying methodological differences. Carotid-femoral PWV is a direct measure of vascular stiffness as determined by the intrinsic stress/strain relationship of the arterial wall and mean arterial pressure. Therefore PWV is considered as the 'gold-standard' [6-8]. In contrast, AIx is an indirect measurement, derived from peripherally recorded pressure waveforms. Using a generalized transfer function the corresponding central arterial waveform is generated from which AIx is determined. Therefore, AIx is influenced by multiple factors such as PWV, heart rate, diastolic blood pressure, peripheral circulation, and endothelial function [7,8]. Furthermore, its discriminatory value may be less in the elderly [25,26], whereas also the use of the generalized transfer function may be inappropriate in certain populations [25-28]. In fact, Hope et al. recently evaluated the validity of this method found in patients with diabetes and revealed that estimation of central pressures was prone to substantially greater error in this population [27]. Similar differences in accuracy have also been reported in relation to gender, indicating that AIx might be a less representative marker of vascular stiffness as compared to PWV [25,26]. Conceivably, the weaker association between AIx and CAD as compared to PWV

may therefore be explained by the fact that our study was performed in patients with diabetes while also including a high percentage of female patients.

### **Clinical implications and perspectives**

At present, screening of asymptomatic patients with diabetes for CAD remains controversial. Thus far, the majority of available data are based on CAD detection using SPECT MPI [3,4]. In the present study, the prevalence of abnormal MPI was 38%. In contrast, the recent DIAD trial demonstrated a much lower rate of abnormal MPI with only few patients having severe MPI defects [5,29]. To a large extent, this discrepancy may be explained by differences in baseline characteristics of the enrolled patients. Importantly, cardiac event rates were low in the DIAD study and not significantly reduced by a MPI based screening strategy. Nevertheless, in the small group of patients with abnormal MPI, a stepwise increase in event rates was observed with increasing MPI abnormality. Of note, hard event rates were 2% in patients with normal scans but increased to 12% in patients with at least moderately abnormal MPI scans. In contrast to the general asymptomatic diabetic population, these high risk patients may benefit from screening, as also suggested by the bypass angioplasty revascularization investigation BARI 2 diabetes trial [30,31]. In this trial no survival benefit was shown in patients undergoing early coronary revascularization as compared to intensive medical treatment. However, among high risk patients selected for coronary artery bypass grafting, prompt revascularization reduced major cardiovascular events as compared with medical therapy. Accordingly, these observations indicate that while routine screening for abnormal MPI may not be effective in asymptomatic patients with diabetes, selective screening strategies are warranted to identify the small but high risk subgroup within this population. In this regard, our current study may provide valuable data for the design of such strategies. Assessment of vascular stiffness by means of PWV was shown to accurately identify patients with a high-risk for severe MPI defects. Accordingly, further screening in patients with elevated PWV may be recommended. On the other hand, when using a slightly lower cut-off value, PWV was also shown to have a high negative predictive value, indicating that PWV can accurately rule out severe MPI defects. Therefore, further evaluation in patients with a negative PWV study may be safely omitted. Due to its low costs and non-invasive nature, PWV may represent a practical first-line tool to differentiate patients with a higher and lower likelihood of having abnormal MPI in this regard.

A number of limitations must be acknowledged in the current study. Some of the observed MPI defects may be attributed to artifact attenuation. However, regional wall motion on gated SPECT images was analyzed for optimal differentiation between true

MPI defects and attenuation artifacts. Evidently, larger prospective studies are needed to demonstrate the effectiveness of this strategy in terms of costs and outcome.

### **CONCLUSION**

Vascular stiffness as non-invasively assessed by PWV is related with severely abnormal myocardial perfusion in asymptomatic patients with diabetes. Accordingly, PWV could be a practical tool to identify patients at higher risk for CAD and who could benefit from further screening.



**REFERENCES**

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004;27(5):1047-53.
2. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida. American Diabetes Association. *Diabetes Care* 1998;21(9):1551-9.
3. Kang X, Berman DS, Lewin HC, Cohen I, Friedman JD, Germano G, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. *Am Heart J* 1999;138(6 Pt 1):1025-32.
4. Miller TD, Rajagopalan N, Hodge DO, Frye RL, Gibbons RJ. Yield of stress single-photon emission computed tomography in asymptomatic patients with diabetes. *Am Heart J* 2004;147(5):890-6.
5. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. *JAMA* 2009;301(15):1547-55.
6. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. *Circulation* 2003;107(1):139-46.
7. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J* 2006;27(21):2588-605.
8. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. *Diabetologia* 2008;51(4):527-39.
9. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. *Circulation* 2006;113(5):657-63.
10. Weber T, Auer J, O'rouke MF, Kvas E, Lassnig E, Berent R, et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. *Circulation* 2004;109(2):184-9.
11. Weber T, Auer J, O'rouke MF, Kvas E, Lassnig E, Lamm G, et al. Increased arterial wave reflections predict severe cardiovascular events in patients undergoing percutaneous coronary interventions. *Eur Heart J* 2005;26(24):2657-63.
12. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation* 2006;113(9):1213-25.
13. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. *Circulation* 2006;113(5):664-70.

14. Rose G, McCartney P, Reid DD. Self-administration of a questionnaire on chest pain and intermittent claudication. *Br J Prev Soc Med* 1977;31(1):42-8.
15. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2003;26 Suppl 1:S5-20.
16. Hansen CL, Goldstein RA, Akinboboye OO, Berman DS, Botvinick EH, Churchwell KB, et al. Myocardial perfusion and function: single photon emission computed tomography. *J Nucl Cardiol* 2007;14(6):e39-e60.
17. Petretta M, Acampa W, Evangelista L, Daniele S, Ferro A, Cuocolo A. Impact of inducible ischemia by stress SPECT in cardiac risk assessment in diabetic patients: rationale and design of a prospective, multicenter trial. *J Nucl Cardiol* 2008;15(1):100-4.
18. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. *J Hypertens* 1998;16(12 Pt 2):2079-84.
19. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. *Arterioscler Thromb Vasc Biol* 2003;23(4):554-66.
20. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. *Hypertension* 2009;54(6):1328-36.
21. Fukui M, Kitagawa Y, Nakamura N, Mogami S, Ohnishi M, Hirata C, et al. Augmentation of central arterial pressure as a marker of atherosclerosis in patients with type 2 diabetes. *Diabetes Res Clin Pract* 2003;59(2):153-61.
22. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am Coll Cardiol* 2010;55(13):1318-27.
23. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? *Circulation* 2002;106(16):2085-90.
24. Hatsuda S, Shoji T, Shinohara K, Kimoto E, Mori K, Fukumoto S, et al. Regional arterial stiffness associated with ischemic heart disease in type 2 diabetes mellitus. *J Atheroscler Thromb* 2006;13(2):114-21.
25. Fantin F, Mattocks A, Bulpitt CJ, Banya W, Rajkumar C. Is augmentation index a good measure of vascular stiffness in the elderly? *Age Ageing* 2007;36(1):43-8.
26. Hope SA, Antonis P, Adam D, Cameron JD, Meredith IT. Arterial pulse wave velocity but not augmentation index is associated with coronary artery disease extent and severity: implications for arterial transfer function applicability. *J Hypertens* 2007;25(10):2105-9.

27. Hope SA, Tay DB, Meredith IT, Cameron JD. Use of arterial transfer functions for the derivation of central aortic waveform characteristics in subjects with type 2 diabetes and cardiovascular disease. *Diabetes Care* 2004;27(3):746-51.
28. Lacy PS, O'Brien DG, Stanley AG, Dewar MM, Swales PP, Williams B. Increased pulse wave velocity is not associated with elevated augmentation index in patients with diabetes. *J Hypertens* 2004;22(10):1937-44.
29. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. *Diabetes Care* 2004;27(8):1954-61.
30. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. *Circulation* 2009;120(25):2529-40.
31. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009;360(24):2503-15.

